An Australian hearing implant pioneer continues to tell investors there are better times ahead, despite its share price falling by more than 50 per cent from around $300 a year ago.
Cochlear struggled through the 2025/26 financial year, culminating in a 62 per cent fall in annual net profit to $147.3 million.